Lymphoma & Plasma Cell Disorders
From the Journals
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
News
Predicting early outcomes in DLBCL
Measurement of circulating tumor DNA (ctDNA) could be a new and useful tool for predicting survival outcomes and response to therapy in patients...
From the Journals
Fracture risk linked to mortality in women with myeloma
Researchers identified osteoporosis as an important prognostic factor in postmenopausal women.
News
NICE says CAR T-cell therapy isn’t cost-effective
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending against the use of axicabtagene ciloleucel (...
News
EC approves CAR T-cell therapy for DLBCL, PMBCL
The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (Yescarta®) to treat two...
From the Journals
ctDNA predicts early outcomes in DLBCL
Adding measurements of circulating tumor DNA to established risk factors could help create a profile of an overall picture of likely outcomes.
News
FDA approves ibrutinib with rituximab in Waldenström’s macroglobulinemia
Ibrutinib is already approved as a single agent in Waldenstrom’s macroglobulinemia.
News
EC approves CAR T-cell therapy for ALL, DLBCL
The European Commission (EC) has granted approval for tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy targeting CD19...
News
FDA approves new use for ibrutinib in WM
The US Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica®) for use in combination with rituximab to treat adults with...
News
Elotuzumab under review for relapsed/refractory myeloma
The Food and Drug Administration is expected to make an approval decision by the end of 2018.
News
Study reveals ‘complete mental health’ among cancer survivors
New research suggests cancer survivors are just as likely as people without a history of cancer to have complete mental health (CMH), which is...